Table 6 Independent associations of autoantibodies with specific sets of clinical features, therapeutic outcomes, and myositis course by stepwise multiple logistic regression in 100 patients with autoimmune myositis

Anti-Jo-1^b

Interstitial lung disease

14.5

3.52 to 59.78

<0.001

Arthritis

11.6

2.92 to 45.65

<0.001

Fever

9.7

2.72 to 34.91

<0.001

Puffy hands

9.6

2.82 to 32.92

<0.001

Associated CTD

0.14

0.03 to 0.70

0.016

Response to prednisone alone

0.04

0.01 to 0.32

0.002

Need for second line drug

25.3

4.24 to 150

<0.001

Anti-fibrillarin

Raynaud's phenomenon

10.9

2.83 to 42.60

<0.001

Any lung involvement

3.5

1.01 to 12.39

0.050

Associated CTD

4.1

1.14 to 14.50

0.031

Anti-U1RNP

Raynaud's phenomenon

9.8

2.28 to 42.59

0.002

Arthritis

5.8

1.74 to 19.18

0.004

Sclerodactily

6.8

2.03 to 22.49

0.001

Associated CTD

6.8

1.76 to 26.55

0.006

Associated SSc

6.1

1.83 to 20.26

0.003

Monophasic myositis course

8.1

1.39 to 46.7

0.020

SSc autoantibodies

Telangiectasias

19.3

2.05 to 181.51

0.010

Sclerodactyly

8.6

1.88 to 39.60

0.005

Scleroderma proximal to MCP

5.3

1.07 to 26.78

0.041

Associated SSc

5.8

1.29 to 25.78

0.022

Anti-Ro or anti-Ro52

Response to prednisone alone

6.2

1.23 to 31.64

0.027

Need for second line drug

0.12

0.03 to 0.54

0.006